| Literature DB >> 34855510 |
Catherine J Reynolds1, Joseph M Gibbons2, Corinna Pade2, Áine McKnight2, Daniel M Altmann3, Rosemary J Boyton1,4, Kai-Min Lin1, Diana Muñoz Sandoval1, Franziska Pieper1, David K Butler1, Siyi Liu1, Ashley D Otter5, George Joy6, Katia Menacho6, Marianna Fontana7, Angelique Smit7, Beatrix Kele6, Teresa Cutino-Moguel6, Mala K Maini8, Mahdad Noursadeghi8, Tim Brooks5, Amanda Semper5, Charlotte Manisty6,9, Thomas A Treibel6,9, James C Moon6,9.
Abstract
The impact of the initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting strain on downstream immunity to heterologous variants of concern (VOCs) is unknown. Studying a longitudinal healthcare worker cohort, we found that after three antigen exposures (infection plus two vaccine doses), S1 antibody, memory B cells, and heterologous neutralization of B.1.351, P.1, and B.1.617.2 plateaued, whereas B.1.1.7 neutralization and spike T cell responses increased. Serology using the Wuhan Hu-1 spike receptor binding domain poorly predicted neutralizing immunity against VOCs. Neutralization potency against VOCs changed with heterologous virus encounter and number of antigen exposures. Neutralization potency fell differentially depending on targeted VOCs over the 5 months from the second vaccine dose. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOC, with implications for future-proof next-generation vaccines.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34855510 DOI： 10.1126/science.abm0811
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728